Technical Analysis for BLTE - Belite Bio, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Sell Signal | Bearish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Cup with Handle | Other | -0.93% | |
| Narrow Range Bar | Range Contraction | -0.93% | |
| Inside Day | Range Contraction | -0.93% | |
| Wide Bands | Range Expansion | -0.93% | |
| Overbought Stochastic | Strength | -0.93% | |
| Pocket Pivot | Bullish Swing Setup | -1.15% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 22 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
| Down 2 % | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/08/2024
Belite Bio, Inc. Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Diabetes Drug Development Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Liver Disease Oral Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 48.6 |
| 52 Week Low | 11.05 |
| Average Volume | 38,779 |
| 200-Day Moving Average | 38.01 |
| 50-Day Moving Average | 40.77 |
| 20-Day Moving Average | 38.61 |
| 10-Day Moving Average | 41.39 |
| Average True Range | 2.13 |
| RSI (14) | 60.63 |
| ADX | 23.4 |
| +DI | 20.36 |
| -DI | 18.90 |
| Chandelier Exit (Long, 3 ATRs) | 37.05 |
| Chandelier Exit (Short, 3 ATRs) | 37.40 |
| Upper Bollinger Bands | 45.32 |
| Lower Bollinger Band | 31.91 |
| Percent B (%b) | 0.81 |
| BandWidth | 34.71 |
| MACD Line | 0.85 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.841 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.68 | ||||
| Resistance 3 (R3) | 44.62 | 43.93 | 44.36 | ||
| Resistance 2 (R2) | 43.93 | 43.46 | 43.96 | 44.26 | |
| Resistance 1 (R1) | 43.37 | 43.16 | 43.03 | 43.43 | 44.15 |
| Pivot Point | 42.68 | 42.68 | 42.51 | 42.71 | 42.68 |
| Support 1 (S1) | 42.12 | 42.21 | 41.78 | 42.18 | 41.45 |
| Support 2 (S2) | 41.43 | 41.91 | 41.46 | 41.34 | |
| Support 3 (S3) | 40.87 | 41.43 | 41.24 | ||
| Support 4 (S4) | 40.93 |
